Medtronic secured CE Mark for its MiniMed 780G system, a closed loop insulin pump system for the treatment of type 1 diabetes in people age 7 to 80 years. Medtronic’s own SmartGuard algorithm and MD-Logic, an algorithm developed by a small Israeli firm called DreaMed Diabetes, automatically delivers both basal insulin and correcting boluses every five minutes, if necessary.
The MiniMed 780G system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL (5.5 mmol/L) — lower than any other advanced hybrid closed loop system — and is designed to help stabilize blood sugar levels and further improve glucose control, reports Medtronic.
“We wanted to design a system that further simplifies diabetes management and adapts to people’s life with the goal of enhancing their experience in a seamless way,” said Sean Salmon, Executive Vice President and President of the Diabetes Group at Medtronic.
Patients who participated in the clinical study provided feedback that the MiniMed 780G system “made life with diabetes and control so much easier” and that it made “life significantly easier.”
The MiniMed 780G system was designed to be easy to use by requiring less input from the user. With the addition of Bluetooth® connectivity, the MiniMed 780G system will enable users and their care partners to see real-time glucose data and trends on compatible iOS and Android smartphones via apps.
“I am incredibly proud of the strong collaboration that resulted in this meaningful step forward with the MiniMed 780G system, which the clinical trial has demonstrated to be a beneficial tool for a wide range of patients and particularly adolescents,” said Professor Moshe Phillip, director of the Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children’s Medical Center of Israel, co-founder and chief science officer, DreaMed Diabetes.
The system is expected to begin shipping this Fall in select countries in Europe. In the United States, the MiniMed 780G system is investigational use only and not approved for sale.
The MiniMed 780G system enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL (5.5 mmol/L) — lower than any other advanced hybrid closed loop system — and is designed to help stabilize blood sugar levels and further improve glucose control.
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Dublin, Ireland-based Medtronic is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries.